CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended				6 Months Ended
	Mar. 31, 2022	Dec. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Mar. 31, 2022	Mar. 31, 2021
Operating Expenses:
Research And Development	$ 6,523,817		$ 5,221,514		$ 12,606,984	$ 10,636,274
General And Administrative	3,028,042		3,311,484		5,788,250	6,627,640
Total Operating Expenses	9,551,859		8,532,998		18,395,234	17,263,914
Operating Loss	(9,551,859)		(8,532,998)		(18,395,234)	(17,263,914)
Gain (loss) On Derivative Instruments	2,195		(3,041,017)		(366,791)	(2,108,181)
Other Non-operating Gain	0		553,630		30,793	(675,236)
Interest Expense, Net	(273,828)		(260,735)		546,862	521,125
Net Loss	$ (9,823,492)	$ (8,782,606)	$ (11,281,120)	$ (7,936,864)	$ (18,606,098)	$ (19,217,984)
Net Loss Per Common Share - Basic And Diluted	$ (0.23)		$ (0.28)		$ (0.43)	$ (0.49)
Weighted Average Common Shares Outstanding - Basic And Diluted	43,122,671		40,047,273		43,100,070	39,351,194